UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
Discovery and Development of Therapeutic TACE (ADAM17) Antibodies Conference paper
Kwok, H. F., Botkjaer, K., Tape, C., Huang, Y., McCafferty, J., Murphy, G.. Discovery and Development of Therapeutic TACE (ADAM17) Antibodies[C], 2015.
Authors:  Kwok, H. F.;  Botkjaer, K.;  Tape, C.;  Huang, Y.;  McCafferty, J.; et al.
Favorite |  | Submit date:2022/06/02
Cross-Reactive  Anti-TACE Antibody  Mouse Models  
Targeting the sheddase activity of Adam17 by an Anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation Journal article
Huang Y., Benaich N., Tape C., Kwok H.F., Murphy G.. Targeting the sheddase activity of Adam17 by an Anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation[J]. International Journal of Biological Sciences, 2014, 10(7), 702-714.
Authors:  Huang Y.;  Benaich N.;  Tape C.;  Kwok H.F.;  Murphy G.
Favorite | TC[WOS]:38 TC[Scopus]:44 | Submit date:2018/12/19
Adam17  Cell Proliferation And Motility  Her Receptor And ligAnds  Inhibitory Antibody  
Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy Journal article
Kwok, H. F., Botkjaer, K. A., Tape, C. J., Huang, Y., McCafferty, J., Murphy, G.. Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy[J]. Protein engineering, design & selection : PEDS Oxford University Press, 2014, 179-190.
Authors:  Kwok, H. F.;  Botkjaer, K. A.;  Tape, C. J.;  Huang, Y.;  McCafferty, J.; et al.
Favorite |   IF:2.6/2.0 | Submit date:2022/06/02
anti-TACE antibody  exosite  immunoreactivity  phage-display randomization libraries  sub-nanomolar affinity